Predicting SSRI Efficacy in Veterans With PTSD
4상
조기 종료
NCT04183205
| 대상 질환 | Posttraumatic Stress Disorder, Major Depressive Disorder |
|---|
| 임상 단계 | 4상 |
|---|
| 스폰서 | VA Office of Research and Development |
|---|
| 상태 | 조기 종료 |
|---|
| 참여자 수 | 19 명 |
|---|
| 중재(약물) | LDAEP, sertraline |
|---|
| 시작일 | 2019년 9월 11일 |
|---|
| 완료일 | 2025년 3월 30일 |
|---|
| 결과 공개일 | 2026년 5월 22일 |
|---|
요약
This is a research study to examine the effectiveness of a brief screening method that may predict which people with posttraumatic stress disorder (PTSD) or depression are most likely to show a positive response to selective serotonin reuptake inhibitor (SSRI) medications. Participants will be recruited over approximately 5.25 years, until at least 94 participants complete the 17 week study.
Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) After 14 Weeks of the Medication Trial Predicted by Pretreatment LDAEP Slope (Calculated With P200 at the PZ Site) and Controlling for Baseline CAPS Score
CAPS score administered 14 weeks after starting the medication trial, controlling for baseline CAPS score · Scores on a scale
| Sertraline Arm | 10.8 ± 9.95 Scores on a scale |
|---|
Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) After 14 Weeks of the Medication Trial as Predicted by Pretreatment LDAEP Slope (Calculated With P200 at the CZ Site) and Controlling for Baseline CAPS Score
CAPS score administered 14 weeks after starting the medication trial, controlling for baseline CAPS score · Scores on a scale
| Sertraline Arm | 10.8 ± 9.95 Scores on a scale |
|---|
Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) After 14 Weeks of the Medication Trial as Predicted by Pretreatment LDAEP Slope (Calculated With P200 at the FZ Site) and Controlling for Baseline CAPS Score
CAPS score administered 14 weeks after starting the medication trial, controlling for baseline CAPS score · Scores on a scale
| Sertraline Arm | 10.8 ± 25.7 Scores on a scale |
|---|
BENITIONS에서 보기
ClinicalTrials.gov 원문 보기
같은 질환의 다른 임상
전체 임상
이 페이지는 ClinicalTrials.gov의 공개 데이터를 정리한 것입니다. 의학적 조언이 아니며 투자 권유나 자문도 아닙니다. 반드시 전문의와 상담하세요.